Scrip brings you market intelligence that goes beyond the headlines and focusses on delivering insight and analysis on the whole of the drug discovery, development and product life cycle value chain. Scrip gives you access to the latest licensing opportunities, partnership deals, company developments and constantly tracks product approvals across multiple therapy areas and product types.
With an unparalleled global network of contributors, Scrip is the trusted, comprehensive source of business critical market and competitor insights for the commercial pharmaceutical industry. It delivers deep insights and analysis about global commercial, business and finance developments and is the go-to- source for the industry.
A subscription will give you increased content direct from editorial bureaus in China, India, Japan, Korea, Australia and the Pacific Rim with daily analysis of critical developments in these and other key markets in the AP region.
With access to English-language summaries of news about your company and competitors from the Chinese and Japanese press, you'll always be kept well informed on these and other key emerging markets.
Scrip now also publishes in-depth profiles of leading-edge start-up companies including new trends in business, technology, and financing. This will help you to identify new investment opportunities, create technology/product ideas and help you understand key trends in company start-ups and plan strategically for the future.
Leading industry insight on a leading industry platform
What’s more, Scrip is published on a new user-friendly, interactive and responsive website. It allows you to access a large amount of relevant content from one place. The ability to create custom email alerts, numerous ways to refine and target search results, and simple tools to collect, send and share content allows you to tailor the service to your exact requirements.
Related articles, deals, companies, regions, therapy areas and other subjects are listed on the same page. This means that you can identify, find and read the content without having to look for it, making the website a valuable time saving resource.
Subscribe today and get access to:
- Over 20 global analysts publishing real-time analysis accessible on mobile, tablet and PC.
- Unique perspective from the US, Europe and developments in Asia Pacific.
- In-depth profiles of leading-edge companies assessing new trends and technologies
- Company Developments: Including M&A, deals, financial results, partnerships and more.
- Product Developments: Including clinical trial results, approvals, launches, and postmarketing updates – so you can drive your own new product strategy.
- Scrip Pipeline Watch: R&D progress for essential competitor data and drug strategy development.
- Trend Spotting – Market Access and Therapeutic Areas: reporting from key conferences; interviews with key opinion leaders.
- Unique access to Informa’s suite of Pharma intelligence databases provide exclusive overviews and market forecasts so you can monitor target disease areas and compare strategies for pricing and reimbursement.
- Financial Markets: Stockwatch column with our unique view of developments and activities and how they impact share prices and deals.
- Scrip 100 – Dive deep into company analysis with Scrip 100, our annual ranking of the top 100 pharmaceutical companies in the world.
- Scrip Asia 100 that dissects who’s who in the growing APAC region annually.
- Scan headlines to be up on the latest, and tailor the service to your specific needs with refined targeted searches, and custom email alerts and RSS feeds so you never miss a development.
- “Ask the Analyst” exclusive client service to find out more about market access topics, developments, or trends to support presentations, proposals, or business critical decisions where your credibility is on the line.
To Speak with a Sales Representative:
If you would like to speak with one of our knowledgeable Sales Representatives, please reach out as follows:
- Email: PharmaNewsSales@informa.com
- Phone (US) +1 212-520-2765
- Phone (UK & Europe): +44 (0) 20 7017-4191
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.